PD-1 Antibodies Activate Brown Adipose Tissue: New Insights into Cardiovascular Protection During Immunotherapy

How Do PD-1 Antibodies Influence Metabolic and Cardiovascular Dynamics?

The impact of PD-1 antibodies on brown adipose tissue metabolism and cardiovascular risk has been revealed in a groundbreaking clinical study, potentially offering new approaches to monitoring and managing cardiovascular complications in cancer patients receiving immunotherapy.

In this retrospective cohort study conducted at Fujian Provincial Hospital and Fujian Cancer Hospital between January 2019 and January 2024, researchers investigated how programmed cell death protein 1 (PD-1) antibody therapy affects brown adipose tissue (BAT) activity and its relationship to cardiovascular parameters. The study included 68 cancer patients (54 males, 14 females) who underwent PET/CT scans before and after receiving PD-1 antibody treatment, providing a unique opportunity to assess metabolic changes in different adipose tissue compartments.

What Are the Key Metabolic and Cardiovascular Findings?

The findings revealed significant increases in metabolic activity across all adipose tissue types following PD-1 antibody therapy. Brown adipose tissue (BAT) showed the most pronounced change, with maximum standardized uptake values (SUVmax) increasing from 1.40±0.40 to 2.36±0.91 (P<0.001). Similar significant increases were observed in visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT). Representative PET/CT images clearly demonstrated enhanced BAT activity in the supraclavicular region post-treatment, confirming the metabolic activation of this thermogenic tissue.

Concurrent with these changes in adipose tissue metabolism, patients exhibited significant alterations in cardiovascular and metabolic parameters. The arterial stiffness index (ASI), calculated as (Total cholesterol-HDL-C)/HDL-C, increased from 3.35±1.05 to 3.92±1.39 (P<0.001). Lipid profiles showed elevations in triglycerides (1.46±0.97 to 1.79±1.20 mmol/L, P<0.05), total cholesterol (4.80±1.17 to 5.26±1.41 mmol/L, P<0.05), and LDL-C (3.19±0.85 to 3.50±1.08 mmol/L, P<0.05). Cardiac troponin T and thyroid-stimulating hormone levels also increased significantly following treatment, indicating widespread metabolic and endocrine effects of PD-1 antibody therapy.

Perhaps the most clinically relevant finding emerged from correlation analyses, which revealed a significant inverse relationship between BAT activity and arterial stiffness index after treatment (r=-0.321, P=0.011). Multivariate linear regression identified arterial stiffness index (β=-1.208, P=0.009) and HDL-C concentration (β=-1.074, P=0.038) as independent determinants of BAT metabolic activity. These associations suggest that enhanced BAT activity may potentially counteract the adverse cardiovascular effects of PD-1 antibody therapy, offering a protective mechanism against increased arterial stiffness.

Which Rigorous Methods Underpinned the Study?

The study utilized a standardized BAT activity quantification protocol with controlled pre-scanning parameters including ambient temperature (19-22°C), fasting duration (>6h), and glycemic status. This methodological rigor established two pivotal assessment timepoints: pre-treatment baseline and early therapy phase (4 weeks), providing a robust framework for dynamic BAT activity monitoring in future clinical applications. The researchers measured SUVmax in three distinct anatomical regions: the supraclavicular fossa (for BAT), perirenal area (for VAT), and lumbosacral region (for SAT).

Prior to PD-1 antibody therapy, BAT metabolic activity exhibited significant inverse correlations with both venous plasma glucose levels (r=-0.301, P=0.016) and free thyroxine (FT4) concentrations (r=-0.293, P=0.031). After treatment, this correlation pattern shifted notably, with BAT activity becoming negatively correlated with arterial stiffness index and positively correlated with free triiodothyronine (FT3) levels (r=0.379, P=0.003). For visceral adipose tissue, post-treatment activity was inversely correlated with free thyroxine (r=-0.262, P=0.047), while subcutaneous adipose tissue showed a significant inverse correlation with male sex (r=-0.259, P=0.037).

Could BAT Activity Serve as a Biomarker for Cardiovascular Risk?

The study proposes several potential mechanisms through which PD-1 antibodies might influence BAT function. The researchers suggest that disruption of the PD-1/PD-L1 signaling axis could alter the immune microenvironment within adipose tissue, modifying the infiltration and functional states of immune cells such as macrophages and T lymphocytes. This immune remodeling could subsequently affect the local cytokine milieu, ultimately impacting UCP1 expression and mitochondrial activity in BAT. Alternatively, immune checkpoint inhibition might potentiate BAT activation through immune system disinhibition, altering cytokine release profiles that indirectly modulate central sympathetic tone or directly target adrenergic receptors on adipocytes.

These findings have substantial clinical implications for cancer patients receiving immune checkpoint inhibitor therapy. The arterial stiffness index is an internationally validated predictor of cardiovascular risk, and its increase following immunotherapy is concerning. However, the negative correlation between BAT activity and ASI suggests that BAT activation might serve as a compensatory mechanism that protects against atherosclerosis. This aligns with previous research showing that BAT activation via β3-adrenergic receptor stimulation protects hyperlipidemic mice from atherosclerotic damage.

The study authors propose that PET/CT-derived BAT SUVmax measurements could serve as a novel biomarker for cardiovascular risk stratification in patients receiving immunotherapy. This approach might enable the identification of patients with low baseline BAT activity prior to immune checkpoint inhibitor therapy who may benefit from intensified cardiovascular monitoring. Furthermore, longitudinal tracking of BAT activity through serial PET/CT scans could more effectively predict long-term cardiovascular risk progression and therapeutic efficacy.

Interestingly, the researchers noted several case reports describing acquired generalized lipodystrophy (AGL) in patients following PD-1 antibody therapy, which seems contradictory to the enhanced adipose tissue activity observed in this study. They hypothesize that PD-1 antibodies might mediate dichotomous effects via different immune cell subsets: some subsets may induce adipocyte apoptosis leading to white adipose tissue atrophy, while others could promote BAT activation. This paradoxical observation warrants further investigation into the complex immunometabolic effects of checkpoint inhibitor therapy.

The central innovation of this study lies in the first systematic demonstration of PD-1 antibody-mediated activation of BAT within a clinical cohort while establishing an inverse correlation between BAT activity and arterial stiffness. This finding gains further significance in light of previous work demonstrating exacerbated atherosclerotic lesions in PD-L1 knockout mice, indicating that the PD-1/PD-L1 axis serves an atheroprotective role. Consequently, blockade of this pathway by PD-1 antibody therapy may heighten atherosclerotic risk, which could potentially be counteracted by enhanced BAT activity.

What Limitations Should Clinicians Consider?

Despite its innovative findings, the study has several limitations. The retrospective design limits causal inferences, and PET/CT might underestimate BAT metabolic activity compared to more direct measurements. Additionally, the study was conducted in a subtropical region (Fujian Province, China), which might limit generalizability to populations in different climatic conditions. The authors acknowledge these limitations and call for prospective studies to validate their findings.

What Future Directions Arise from This Study?

Could the integration of BAT activity measurement into routine clinical assessment refine risk stratification and management strategies for cancer patients receiving immunotherapy? This question becomes increasingly relevant as immune checkpoint inhibitors become standard treatments across multiple cancer types. The growing recognition of cardiovascular complications as significant contributors to morbidity in cancer survivors underscores the importance of identifying early biomarkers and protective mechanisms.

How might this emerging understanding of immuno-metabolic crosstalk influence current paradigms in both oncology and cardiovascular care? The intersection of immune regulation and metabolic homeostasis represents a frontier with significant therapeutic potential. As we deepen our understanding of these complex interactions, novel therapeutic targets may emerge that could simultaneously address both cancer progression and treatment-related cardiovascular complications.

In conclusion, this study provides compelling evidence that PD-1 antibody therapy enhances BAT activity in cancer patients, with potential implications for cardiovascular risk management. The inverse relationship between BAT activity and arterial stiffness suggests that BAT activation might mitigate some of the adverse cardiovascular effects of immunotherapy. These findings open new avenues for research into BAT-targeted interventions that could improve cardiovascular outcomes in cancer patients receiving immune checkpoint inhibitor therapy.

Summary

A retrospective cohort study conducted at Fujian Provincial Hospital and Fujian Cancer Hospital (January 2019–January 2024) investigated the effects of PD-1 antibody therapy on brown adipose tissue (BAT) metabolism and cardiovascular parameters in 68 cancer patients. The research revealed that PD-1 antibody treatment significantly increased metabolic activity across all adipose tissue types, with BAT showing the most pronounced change—maximum standardized uptake values increased from 1.40±0.40 to 2.36±0.91 (P<0.001). Concurrent cardiovascular changes included increased arterial stiffness index (from 3.35±1.05 to 3.92±1.39, P<0.001) and elevated lipid profiles. Notably, correlation analyses demonstrated a significant inverse relationship between BAT activity and arterial stiffness index after treatment (r=-0.321, P=0.011), suggesting that enhanced BAT activity may counteract adverse cardiovascular effects of immunotherapy. The study proposes that PET/CT-derived BAT measurements could serve as a novel biomarker for cardiovascular risk stratification in patients receiving immune checkpoint inhibitor therapy, enabling identification of high-risk patients who may benefit from intensified cardiovascular monitoring. These findings highlight the complex immuno-metabolic interactions induced by PD-1 antibodies and suggest that BAT activation might represent a protective mechanism against atherosclerosis in cancer patients undergoing immunotherapy.